

Adaptimmune Therapeutics PLC  
Form 8-K  
July 24, 2017

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **July 20, 2017**

**ADAPT IMMUNE THERAPEUTICS PLC**

(Exact name of registrant as specified in its charter)

**England and Wales**  
(State or other jurisdiction of  
incorporation)

**1-37368**  
(Commission File Number)

**Not Applicable**  
(IRS Employer Identification No.)

**60 Jubilee Avenue, Milton Park  
Abingdon, Oxfordshire OX14 4RX**

**United Kingdom**

(Address of principal executive offices, including zip code)

**(44) 1235 430000**

## Edgar Filing: Adaptimmune Therapeutics PLC - Form 8-K

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.05 Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics.**

On July 20, 2017, the Board of Directors of Adaptimmune Therapeutics plc (the Company or Adaptimmune) approved and adopted a revised and updated Code of Business Conduct and Ethics (the Updated Code), which applies to all directors, officers and employees of the Company. The Updated Code replaced the Company's prior Code of Business Conduct and Ethics adopted in July 2015 and reflects, among other matters, clarifications and revisions relating to conflicts of interest, compliance with laws, reporting and enforcement, and other matters intended to update the Company's Code of Business Conduct and Ethics.

The foregoing summary of the Updated Code does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Updated Code, which is filed as Exhibit 14.1 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Updated Code is available in the Investors section of Adaptimmune's website (<http://www.adaptimmune.com>) under the heading Governance. The information contained on or accessible through the Company's website shall not be deemed to be a part of this Current Report on Form 8-K.

The information contained in Item 9.01 of this Form 8-K, including the attached Exhibit 14.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is furnished as part of this Report on Form 8-K:

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
14.1	Adaptimmune Therapeutics plc Code of Business Conduct and Ethics, effective July 20, 2017

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ADAPT IMMUNE THERAPEUTICS PLC

Date: July 24, 2017

By: /s/ Margaret Henry  
Name: Margaret Henry  
Title: Corporate Secretary

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
14.1	Adaptimmune Therapeutics plc Code of Business Conduct and Ethics, effective July 20, 2017